FNCH Insider Trading Activity and SEC Form 4 Filings
FNCH insider trading summary
No open-market insider purchases or sales of Finch Therapeutics Group, Inc. (FNCH) have been reported on SEC Form 4 in the past 12 months.
Latest FNCH insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Mar 28, 2024 | Jeffery A Smisek | Insider | Sell | $17K (6,642 @ $2.57) |
| Mar 28, 2024 | Jeffery A Smisek | Insider | Sell | $4K (1,600 @ $2.61) |
| Nov 22, 2023 | Jeffery A Smisek | Insider | Sell | $5K (1,470 @ $3.64) |
| Jun 9, 2023 | Susan E Graf | Director | Buy | $1K (5,010 @ $0.27) |
| Feb 21, 2023 | Marc Blaustein | Chief Operating Officer | Sell | $2K (4,619 @ $0.38) |
| Oct 21, 2022 | Joseph Vittiglio | Chief Business & Legal Officer | Sell | $5K (3,636 @ $1.39) |
| Oct 21, 2022 | Marc Blaustein | Chief Operating Officer | Sell | $5K (3,636 @ $1.39) |
| Dec 20, 2021 | Nicholas Haft | Director | Buy | $650K (63,850 @ $10.18) |
| Mar 23, 2021 | Crestovo Investor LLC | Director | Buy | $12.5M (735,294 @ $17.00) |
| Mar 23, 2021 | Chris Shumway | Director | Buy | $12.5M (735,294 @ $17.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.